Atransferrinemia
| Atransferrinemia | |
|---|---|
| autorecessive.svg | |
| Atransferrinemia follows an autosomal recessive pattern of inheritance, meaning both copies of the gene in each cell are defective. | |
| Synonyms | Familial atransferrinemia
|
| Specialty | Hematology |
| Symptoms | Anemia, iron overload |
| Complications | Heart failure, liver damage, arthritis
|
| Causes | Mutations in the transferrin (TF) gene
|
| Diagnosis | Transferrin levels, blood tests, genetic testing, physical examination
|
| Treatment | Apotransferrin therapy |
| Medication | None; iron therapy is contraindicated |
| Prognosis | Manageable with appropriate treatment |
| Frequency | Extremely rare (fewer than 15 cases documented) |
| Deaths | Rare; often due to complications if untreated |



Atransferrinemia is a rare genetic disorder that falls under inborn errors of metal metabolism. It is caused by a deficiency or absence of transferrin, a plasma protein responsible for transporting iron in the bloodstream. A lack of transferrin disrupts iron delivery to cells, leading to anemia and hemosiderosis (iron overload) in organs such as the heart, liver, and pancreas.
Clinical Features[edit]
The primary symptoms of atransferrinemia include:
- Severe microcytic anemia (small, pale red blood cells)
- Iron deposition in organs, leading to:
- Recurrent infections due to weakened immune response.
The anemia is both microcytic and hypochromic, with red blood cells unable to function properly due to insufficient iron delivery.
Pathophysiology[edit]
The transferrin protein, encoded by the TF gene, is crucial for transporting iron to the reticuloendothelial system for erythropoiesis. In atransferrinemia, the absence of transferrin leads to:
- An inability to deliver iron for red blood cell production.
- Excess iron accumulating in the heart, liver, pancreas, and joints, causing tissue damage.
- Elevated serum ferritin levels as the body attempts to bind excess free iron.
Genetics[edit]
Atransferrinemia is inherited in an autosomal recessive manner, meaning a person must inherit defective copies of the TF gene from both parents. Mutations in the TF gene impair the production or function of transferrin. Genetic testing can confirm mutations in affected individuals.
Diagnosis[edit]
Diagnosing atransferrinemia involves:
- Blood tests showing severe anemia with microcytic and hypochromic characteristics.
- Measurement of transferrin levels, which are typically absent or very low.
- Genetic testing to identify mutations in the TF gene.
- Imaging studies to assess iron overload in organs.
Differential diagnosis includes other conditions that cause microcytic anemia, such as iron-deficiency anemia and thalassemia.
Treatment[edit]
The cornerstone of treatment is:
- Apotransferrin therapy: This replaces the missing transferrin protein and restores proper iron transport.
- Management of iron overload:
- Iron chelation therapy may be required to prevent organ damage.
- Avoidance of iron therapy: Oral or intravenous iron supplements are contraindicated, as they exacerbate iron overload without correcting anemia.
Prognosis[edit]
With early diagnosis and appropriate treatment, the prognosis for atransferrinemia is favorable. Left untreated, complications such as cardiac failure and liver cirrhosis can be life-threatening.
Epidemiology[edit]
Atransferrinemia is an extremely rare condition, with fewer than 15 documented cases worldwide. Most cases are identified in consanguineous families due to the autosomal recessive inheritance pattern.
Related Conditions[edit]
See Also[edit]
External Links[edit]
| Inborn error of metal metabolism (E83, 275) | ||||
|---|---|---|---|---|
|
Sponsored Health Resource

W8MD Weight Loss, Sleep & MedSpa
Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.
GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.
- Medical weight loss NYC
- Affordable GLP-1 injections NYC
- Budget GLP-1 weight loss shots Philadelphia
- New Jersey medical weight loss
- NYC medical weight loss blog
- Philadelphia weight loss blog
- Sleep medicine and sleep apnea services
- W8MD MedSpa and wellness
Book a W8MD appointment · View GLP-1 specials
Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian